Germain R N, Williams R M, Benacerraf B
Am J Pathol. 1976 Dec;85(3):661-74.
Tumor-specific cytolytic activity, as measured by the 51Cr release assay, has been demonstrated in the draining lymph node cells from DBA/2 mice bearing the syngeneic P815 mastocytoma or SL2 lymphoma. This lytic activity is mediated by cytolytic T lymphocytes (CTL), since cytotoxicity is eliminated by treatment of the effector cells with anti-Thy 1.2 (theta) serum plus complement but is enhanced or unaffected by anti-Thy 1.2 serum alone, antimouse immunoglobulin plus complement, normal or aggregated mouse immunoglobulin, or removal of adherent cells. The time course of the CTL response has been analyzed and is similar for both P815 and SL2, with a peak around Days 10 to 12 after tumor grafting. Detectable CTL activity then wanes despite continued antigenic stimulation from the growing tumor. The ability of the immunotherapeutic agent Corynebacterium parvum to augment such specific CTL responses is documented as one antitumor pathway by which this agent may act.
通过51Cr释放试验测定，在携带同基因P815肥大细胞瘤或SL2淋巴瘤的DBA/2小鼠引流淋巴结细胞中已证实存在肿瘤特异性细胞溶解活性。这种溶解活性由细胞毒性T淋巴细胞（CTL）介导，因为用抗Thy 1.2（θ）血清加补体处理效应细胞可消除细胞毒性，但单独使用抗Thy 1.2血清、抗小鼠免疫球蛋白加补体、正常或聚集的小鼠免疫球蛋白或去除贴壁细胞对细胞毒性有增强作用或无影响。已分析了CTL反应的时间进程，P815和SL2的情况相似，肿瘤移植后第10至12天左右达到峰值。尽管生长中的肿瘤持续提供抗原刺激，但可检测到的CTL活性随后逐渐减弱。免疫治疗剂短小棒状杆菌增强这种特异性CTL反应的能力被记录为该药剂可能起作用的一种抗肿瘤途径。
